Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + ESHAP in Relapsed/Refractory DLBCL
NCT00568815Phase 2Completed
- Sponsor
- Fudan University
- Start
- Apr 2007
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Fudan University. Started Apr 2007; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00568815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00568815.